Best-In-Class Or First-In-Class: CGRP Inhibitors Line Up To Win The Migraine Market

 
• By Mandy Jackson

Amgen will be the first biopharma company to seek approval for a CGRP inhibitor when it submits a BLA for FDA approval later in the second quarter, but Alder, Lilly, Teva and Allergan are in the running for best-in-class status to treat unmet needs in migraine and other headache markets.

Human brain illustrated with millions of small nerves - Conceptual 3d render

More from Neurological

More from Therapy Areas